Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
An interim overall survival analysis of the novel therapy sitravatinib combined with nivolumab has cleared the way for a continuation of the phase 3 SAPPHIRE study in patients with advanced non-squamous non–small cell lung cancer.
During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
This is the second of 2 articles based on this event.
Michelle Shiller, DO, AP/CP, MGP, describes the process of tissue biopsy testing at her institution from start to finish, and Zosia Piotrowska, MD, explains the likelihood of targetable alterations in cases of mNSCLC in patients with no smoking history.
In this companion article, Dr Paul Bunn discuss the implications from the pooled results of trilaciclib on chemotherapy induced myelosuppression (CIM) and reviews management strategies for patients that might develop neutropenia while on chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).